Submitted by Anonymous (not verified) on 2 October 2025 - 15:00
Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 23, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Takhzyro, lanadelumab, Date of authorisation: 22/11/2018, Revision: 23, Status: Authorised